Johnson & Johnson $JNJ Shares Purchased by Cwm LLC

Key Points

• Cwm LLC increased its stake in Johnson & Johnson by 4.7%, owning 539,187 shares valued at $82,361,000 as of the latest SEC filing.
• The stock has received several analyst upgrades, with Weiss Ratings improving its rating from "hold" to "buy" and UBS raising its target price from $190 to $214.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, representing an annualized yield of 2.7%, with the ex-dividend date set for November 25th.

Cwm LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.7% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 539,187 shares of the company's stock after acquiring an additional 24,269 shares during the period. Cwm LLC's holdings in Johnson & Johnson were worth $82,361,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $218,000. GAMMA Investing LLC raised its position in shares of Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock valued at $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Johnson & Johnson by 6.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company's stock valued at $281,734,000 after purchasing an additional 107,009 shares in the last quarter. Finally, Hanson & Doremus Investment Management raised its position in shares of Johnson & Johnson by 9.7% in the 1st quarter. Hanson & Doremus Investment Management now owns 15,227 shares of the company's stock valued at $2,525,000 after purchasing an additional 1,349 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JNJ. Weiss Ratings raised Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 8th. UBS Group upped their target price on Johnson & Johnson from $190.00 to $214.00 and gave the company a "buy" rating in a research report on Tuesday. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $209.00 price target on shares of Johnson & Johnson in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $193.88.

Johnson & Johnson Price Performance

Shares of JNJ opened at $190.88 on Wednesday. The company has a market cap of $459.70 billion, a P/E ratio of 20.41, a PEG ratio of 2.40 and a beta of 0.40. The stock has a fifty day moving average price of $179.28 and a 200 day moving average price of $164.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.